New clinical trial for Metastatic Breast Cancer

Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year.  Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress.  Biotech Companies in focus today are Regen BioPharma, Inc. , Sanofi SA , Vical Incorporated , RXi Pharmaceuticals Corporation , Rock Creek Pharmaceuticals, Inc.  & Neuralstem, Inc. 

Regen BioPharma, Inc. announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.

"Using the immune system to treat cancer offers great potential in that the immune system destroys tumor cells, but then establishes immunological memory, which constantly patrols the body for rogue cells." Said Dr. Kesari, "Having served as a member of Regen's Scientific Advisory Board,  I am excited to be involved in this collaboration, in which we aim to help expediently address the questions posed by the FDA and allow for clinical entry of dCellVax."